APIs for research and impurities

Amikacin EP Impurity A is a metabolite of amikacin. It is a white crystalline substance with a molecular weight of 269.5. Amikacin EP Impurity A is found in the urine and bile of individuals who have been administered amikacin. It has been shown to be pharmacologically active, inhibiting bacterial growth by binding to DNA-dependent RNA polymerase, thereby preventing transcription and replication.

Varenicline Diamine Impurity - Bio-X ™ is a diamine impurity of varenicline, a medication used for smoking cessation. Varenicline acts as a partial agonist at α4β2 nicotinic acetylcholine receptors, which are involved in the addictive effects of nicotine. Researchers utilize this compound to study its effects on nicotine addiction and develop potential treatments for smoking cessation. This impurity is used as a reference standard or analytical tool in the quality control and manufacturing process of varenicline and serves as an important marker for ensuring the purity and consistency of varenicline during its production, helping to maintain the medication's safety and efficacy for patients seeking to quit smoking.

Cinacalcet is a drug product that is used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. It is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. The high frequency of human activity has been shown using a patch-clamp technique on human erythrocytes. Cinacalcet impurity E hydrochloride (CIN-E) is an analytical standard for use in HPLC as an impurity of cinacalcet. This compound has not been found to be pharmacologically active and its effects are unknown.

9-Hydroxymethyl-10-hydroxy camptothecin (9OHC) is a metabolite of camptothecin. It is an impurity with a purity of 99.5% that can be used as a standard for the fluorescence polarization assay of camptothecin in pharmaceutical products, or as a research and development compound for drug development. 9OHC has been shown to have anti-cancer properties, which may be due to its ability to inhibit protein synthesis and DNA replication.

Lercandipine Impurity A is a metabolite of the drug lercandipine. It is synthesized in the body by oxidation at the benzylic position of the cinnamoyl moiety. This impurity may be present in lercandipine-containing drugs and products, as well as in other drugs and products containing lercandipine. Lercandipine Impurity A has been shown to inhibit the metabolism of lercandipine and may also have anti-inflammatory properties. It is used as an analytical standard for HPLC, pharmacopoeia, drug development, and metabolism studies. Lercandipine Impurity A is found in the following: -Impurities of Lercandipine -Custom synthesis -Lercandipine Drug Product -Synthetic -High purity -Pharmacopoeia -Drug development

Desisopropyl disopyramide oxalate is a racemic mixture of the enantiomers, (+)-desisopropyl disopyramide and (-)-desisopropyl disopyramide. It is an anticholinergic drug that can be used to treat chronic depression. Desisopropyl disopyramide binds to two different sites on the enzyme p-450 and inhibits the metabolism of drugs such as benzodiazepines and tricyclic antidepressants. Desisopropyl disopyramide has been shown to have an inhibitory effect on activated muscarinic receptors in animal models, but not in humans. This drug also has anti-cholinergic effects and is used for the treatment of pediatric patients with spasticity.

Stability Hygroscopic Applications A centrally-acting cough suppressant. It has local anesthetic and antihistamine properties, and may have anticholinergic effects at high doses. References Yuizono, T., et al.: Yakugaku Zasshi, 87, 915 (1967), Nomura, A., et al.: Oyo Yakuri, 8, 119 (1974),